Top Midday Gainers

MT Newswires Live04-02

Cyclerion Therapeutics (CYCN) and Korsana Biosciences, a privately-held biotechnology firm, said Wednesday they have entered into a definitive merger agreement for an all-stock transaction.

Korsana secured commitments for an oversubscribed private investment that is expected to result in gross proceeds of about $380 million from a syndicate of investors, according to a statement.

Shares of Cyclerion catapulted 319% as intraday trading volume soared to over 230.2 million from a daily average of about 1.5 million.

Target Hospitality (TH) said Wednesday it expects 2026 revenue of $360 million to $370 million, compared with its earlier guidance of $320 million to $330 million. Four analysts surveyed by FactSet expect $328.9 million.

Additionally, the company said it has secured a multiyear lease and services agreement to support the development of a hyperscaler's data center campus in North Texas.

Shares soared 39% as intraday trading volume rose to over 7.5 million from a daily average of roughly 415,000.

TD Synnex (SNX) stands out positively in a "cautious" hardware sector due to strong execution, distribution share gains, and more exposure to cloud infrastructure spending than expected, Morgan Stanley said in a Wednesday note.

The firm said that TD Synnex's fiscal Q1 earnings and fiscal Q2 guidance were ahead of expectations.

Shares of TD Synnex jumped 9% as intraday trading volume climbed to more than 1.1 million from a daily average of about 770,000.

Price: 6.49, Change: +4.94, Percent Change: +318.71

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment